Drugs traditionally used to treat blood pressure and heart disease are to be given to lung disease patients to see if they can be beneficial, in a trial taking place at University Hospitals Birmingham NHS Foundation Trust and coordinated by the University of Aberdeen.
Chronic obstructive pulmonary disease (COPD) is a long term lung disease due to smoking that affects 1.2 million people in the UK. It is the fifth leading cause of death in the UK, resulting in 30,000 fatalities a year.
The condition gradually gets worse and causes narrowing of the airways, which in turn causes breathing problems, and often a persistent cough and chest infections.
There is no cure for COPD – which costs the NHS £1billion per year – and it can be hard to treat.
Sudden “flare-ups” are a feature of the disease which leave sufferers more breathless, wheezy and more likely to cough. These flare-ups shorten life expectancy and impact people’s ability to get on with daily life. Around 60% of the £1billion spent on the condition is used to treat such flare-ups.
Now a trial, being run across multiple UK centres including Aberdeen, Dundee and Birmingham will treat COPD patients with beta-blocker drugs which are more commonly used to treat high blood pressure and heart disease.
There is evidence that beta-blockers can reduce flare-ups in people with COPD, even if they do not also have a heart condition.
Older beta-blockers had lung side-effects but newer, so-called selective beta-blockers targeting the heart are safe for those with COPD to use.
The trial, funded by the UK National Institute for Health Research, will recruit more than 1,500 patients with COPD from 160 centres across the UK including the Queen Elizabeth and Heartlands Hospitals in Birmingham.
Half of the patients will take be given a beta-blocker (bisoprolol) with the other half given a placebo in order to see if the beta-blocker reduces the number of flare-ups.
Dr Simon Gompertz from the Queen Elizabeth Hospital Birmingham said that “The prospect of “repurposing” beta-blockers for use in COPD is very attractive and I am very hopeful that this large collaborative trial will show real benefits for our patients”.
Professor Brian Lipworth of the Scottish Centre of Respiratory Disease, University of Dundee said: “We have already shown that bisoprolol is safe to use in COPD in this trial we will assess if bisoprolol might decrease exacerbations of COPD with the ultimate aim to see if it might improve survival.”
Professor Graham Devereux, from the University of Aberdeen, said: “One of the problems with COPD is that despite improvements in inhalers, COPD continues to be a major problem. The evidence that beta-blockers might help people with COPD is very exciting and a potential game changer in our approach to this disease.”
Dave Bertin of Chest Heart and Stroke Scotland, added: “We are delighted to be involved in this important study. Through our Voices Scotland team we have used the views of people living with COPD to help shape the research.”
For further information about the study, please contact:
Tel: 01224 438 194